Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$24.58 USD

24.58
36,360,635

+0.35 (1.44%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $24.57 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (68 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks News

Zacks Equity Research

3 Companies Competing to Gain Lead in Ovarian Cancer Market

Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.

    Zacks Equity Research

    Stock Market News For Nov 22, 2017

    Benchmarks finished in the green on Tuesday following gains in the technology and healthcare sectors

      Zacks Equity Research

      J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen

      J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.

        Zacks Equity Research

        Amgen (AMGN) Unveils Auto Injector Device for Enbrel in US

        Amgen launched its Enbrel Mini with AutoTouch, a new auto injector device for Enbrel in the United States.

          Zacks Equity Research

          Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion

          Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.

            Zacks Equity Research

            Cancer Space Update: Label Expansion for Three Major Drugs

            This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

              Zacks Equity Research

              AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

              AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.

                Arpita Dutt headshot

                Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day

                Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.

                  Zacks Equity Research

                  Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis

                  CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.

                    Zacks Equity Research

                    The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global

                    The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global

                      Zacks Equity Research

                      Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study

                      Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.

                        Zacks Equity Research

                        Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat

                        Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.

                          Sweta Killa headshot

                          Pharma ETFs Down Post Q3 Earnings

                          The string of earnings beat failed to boost pharma ETFs as they saw rough trading over the past one month.

                            Zacks Equity Research

                            Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus

                            Increased operating expenses mar Aerie's (AERI) Q3 performance.

                              Zacks Equity Research

                              Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND

                              The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.

                                Zacks Equity Research

                                What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?

                                Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business.

                                  Arpita Dutt headshot

                                  Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah

                                  It was all about earnings last week with companies like Pfizer (PFE), Teva and Allergan reporting third quarter results.

                                    Swarup Gupta headshot

                                    Dow 30 Stock Roundup: Chevron, Exxon, Apple Earnings Impress

                                    The Dow continued to notch up gains during a week marked by key legislative developments.

                                      Zacks Equity Research

                                      Key Predictions for Q3 Earnings Reports of MYL, HZNP & KERX

                                      The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if generic maker Mylan and other small companies follow suit.

                                        Zacks Equity Research

                                        Momenta's (MNTA) Biosimilar Study Fails, Q3 Loss Narrows

                                        Momenta Pharmaceuticals (MNTA) study to evaluate a biosimilar version of Orencia failed which overshadowed the third-quarter results.

                                          Zacks Equity Research

                                          AmerisourceBergen (ABC) Beats Q4 Earnings, Issues FY18 View

                                          Solid growth in the Pharmaceutical Distribution Services segment drove AmerisourceBergen's (ABC) top line in the fourth quarter.

                                            Zacks Equity Research

                                            Company News For Nov 1, 2017

                                            Companies in the news are: PFE, UA,AET, ACOR

                                              Zacks Equity Research

                                              Pfizer (PFE) Beats on Q3 Earnings, Raises 2017 EPS View

                                              Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised its adjusted earnings guidance while tightening revenue expectations for 2017.

                                                Zacks Equity Research

                                                Stocks To Watch Out For This Halloween

                                                Stocks To Watch Out For This Halloween

                                                  Mark Vickery headshot

                                                  Will Markets Stay Spooked This Halloween?

                                                  While econ data looks favorable, ahead of the opening bell we also see plenty of strength in Q3 performance.